Lupus nephritis

17 trials 9 recruiting MedDRA PT
17 Registered trials
9 Recruiting
10 Unique sponsors
15 Unique IMPs
15 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 1
— ATC code not specified 12
L Oncology (ATC L) 4
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Complement inhibitor (C5) 1 substance
Immunosuppressant 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Corticosteroid 1 substance
Supportive / diluent 1 substance
Proteasome inhibitor 1 substance
CAR-T cell therapy 1 substance
Monoclonal antibody 1 substance
Calcineurin inhibitor 1 substance
Phase III: 2 Phase II/III: 2 Phase II: 7 Phase I/II: 1 Phase IV: 1 Phase I (Other): 3 Phase I (First in Human): 1

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

2 trials
  • Novartis Pharma AG Commercial
    IANALUMAB
    2023-508559-37-00 9 countries 2022 n=57
    Ended
  • Novartis Pharma AG Commercial
    IANALUMAB
    2024-515280-60-00 5 countries 2025 n=42
    Recruiting

Phase II/III

2 trials
  • Kyverna Therapeutics Inc. Commercial
    KYV-101
    2024-511198-31-00 1 country 2026 n=30 Orphan
    Recruiting
  • Hospital Universitario Rio Hortega Academic
    MSV-ALLO
    2024-514750-67-00 1 country 2022 n=20
    Recruiting

Phase II

7 trials
  • Alexion Pharmaceuticals Inc. Commercial
    VEMIRCOPAN
    2023-504825-38-00 3 countries 2022 n=35
    Ended
  • Alexion Pharmaceuticals Inc. Commercial
    RAVULIZUMAB
    2023-507977-16-00 7 countries 2021 n=87
    Ended
  • Celgene Corp. Commercial
    CC-97540
    2024-519278-37-00 9 countries 2025 n=35
    Halted
  • F. Hoffmann-La Roche AG Commercial
    MYCOPHENOLATE MOFETIL; OBINUTUZUMAB
    2023-505825-15-00 4 countries 2021 n=10
    Recruiting
  • Kezar Life Sciences Inc. Commercial
    METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLATE MOFETIL; WATER FOR INJECTION; ZETOMIPZOMIB
    2022-502227-22-00 7 countries 2023 n=82 Orphan
    Ended
  • Novartis Pharma AG Commercial
    IPTACOPAN; IPTACOPAN HYDROCHLORIDE
    2023-509332-26-00 5 countries 2023 n=48
    Recruiting
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-510150-17-00 13 countries 2024 n=93
    Recruiting

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-510081-27-00 3 countries 2023 n=19
    Ended

Phase IV

1 trial
  • Amsterdam UMC Stichting Academic
    VOCLOSPORIN
    2025-522187-32-01 1 country 2026 n=55
    Recruiting

Phase I (Other)

3 trials
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-518797-13-00 3 countries 2025 n=16
    Ended
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-520222-11-00 3 countries 2026 n=15
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-518288-37-00 3 countries 2025 n=19
    Recruiting

Phase I (First in Human)

1 trial
  • Kyverna Therapeutics Inc. Commercial
    IMP not specified
    2024-513329-22-00 1 country 2023 n=32
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 5 Phase II, Phase III, Phase I/II 3
Kyverna Therapeutics Inc. Commercial 2 Phase II/III, Phase I (First in Human) 1
Century Therapeutics Inc. Commercial 2 Phase I (Other) 1
Alexion Pharmaceuticals Inc. Commercial 2 Phase II 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase I (Other) 1
Celgene Corp. Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase II 1
Kezar Life Sciences Inc. Commercial 1 Phase II 0
Hospital Universitario Rio Hortega Academic 1 Phase II/III 1
Amsterdam UMC Stichting Academic 1 Phase IV 1
New trials by year
2021
2
2022
3
2023
4
2024
1
2025
4
2026
3
← All indication landscapes